Citius Pharmaceuticals Stock Market Value
| CTXR Stock | USD 0.85 0.05 6.25% |
| Symbol | Citius |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Citius Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Citius Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Citius Pharmaceuticals.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in Citius Pharmaceuticals on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding Citius Pharmaceuticals or generate 0.0% return on investment in Citius Pharmaceuticals over 90 days. Citius Pharmaceuticals is related to or competes with SeaStar Medical, Apollomics, Curis, Aditxt, Moleculin Biotech, FibroBiologics Common, and Lunai Bioworks. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of cr... More
Citius Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Citius Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Citius Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 47.9 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 13.83 |
Citius Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Citius Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Citius Pharmaceuticals historical prices to predict the future Citius Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.83) | |||
| Total Risk Alpha | (1.49) | |||
| Treynor Ratio | (0.18) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Citius Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Citius Pharmaceuticals January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 5.36 | |||
| Coefficient Of Variation | (1,386) | |||
| Standard Deviation | 7.43 | |||
| Variance | 55.22 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.83) | |||
| Total Risk Alpha | (1.49) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 47.9 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 13.83 | |||
| Skewness | 0.5288 | |||
| Kurtosis | 2.12 |
Citius Pharmaceuticals Backtested Returns
Citius Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13 % return per unit of risk over the last 3 months. Citius Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Citius Pharmaceuticals' Standard Deviation of 7.43, risk adjusted performance of (0.04), and Mean Deviation of 5.36 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.0, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Citius Pharmaceuticals will likely underperform. At this point, Citius Pharmaceuticals has a negative expected return of -0.85%. Please make sure to confirm Citius Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Citius Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.71 |
Good predictability
Citius Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Citius Pharmaceuticals time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Citius Pharmaceuticals price movement. The serial correlation of 0.71 indicates that around 71.0% of current Citius Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.71 | |
| Spearman Rank Test | 0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Citius Stock
| 0.82 | BMY | Bristol Myers Squibb | PairCorr |
| 0.81 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
| 0.79 | MRK | Merck Company | PairCorr |
| 0.79 | TBPH | Theravance Biopharma | PairCorr |
| 0.73 | JNJ | Johnson Johnson | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.